{ 'indexed': {'date-parts': [[2024, 4, 4]], 'date-time': '2024-04-04T01:11:38Z', 'timestamp': 1712193098768},
'reference-count': 16,
'publisher': 'Massachusetts Medical Society',
'issue': '13',
'license': [ { 'start': { 'date-parts': [[2024, 4, 4]],
'date-time': '2024-04-04T00:00:00Z',
'timestamp': 1712188800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://www.nejmgroup.org/legal/terms-of-use.htm'}],
'funder': [ { 'DOI': '10.13039/100004319',
'name': 'Pfizer',
'doi-asserted-by': 'publisher',
'award': ['N/A']}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2024, 4, 4]]},
'DOI': '10.1056/nejmoa2309003',
'type': 'journal-article',
'created': {'date-parts': [[2024, 4, 3]], 'date-time': '2024-04-03T21:00:29Z', 'timestamp': 1712178029000},
'page': '1186-1195',
'source': 'Crossref',
'is-referenced-by-count': 1,
'title': 'Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19',
'prefix': '10.1056',
'volume': '390',
'author': [ { 'given': 'Jennifer',
'family': 'Hammond',
'sequence': 'first',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Robert J.',
'family': 'Fountaine',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Carla',
'family': 'Yunis',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Dona',
'family': 'Fleishaker',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Mary',
'family': 'Almas',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Weihang',
'family': 'Bao',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Wayne',
'family': 'Wisemandle',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Mary Lynn',
'family': 'Baniecki',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Victoria M.',
'family': 'Hendrick',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Veselin',
'family': 'Kalfov',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-9630-7792',
'authenticated-orcid': False,
'given': 'J. Abraham',
'family': 'Simón-Campos',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'Rienk',
'family': 'Pypstra',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]},
{ 'given': 'James M.',
'family': 'Rusnak',
'sequence': 'additional',
'affiliation': [ { 'name': 'From Global Product Development, Pfizer, Collegeville, PA '
'(J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.); '
'Global Product Development, Pfizer, Lake Mary (C.Y.), and Global '
'Product Development, Pfizer, Tampa (J.M.R.) — both in Florida; '
'Global Product Development, Pfizer, Lexington, KY (D.F.); Global '
'Product Development, Pfizer, New York (M.A., W.B., R.P.); Global '
'Product Development, Pfizer, Lake Forest, IL (W.W.); Early '
'Clinical Development, Pfizer, Cambridge, MA (M.L.B.); '
'Pfizer,...'}]}],
'member': '150',
'reference': [ {'key': 'e_1_3_5_2_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.26326'},
{'key': 'e_1_3_5_3_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.2648'},
{'key': 'e_1_3_5_4_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa1012'},
{'key': 'e_1_3_5_5_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1985'},
{'key': 'e_1_3_5_6_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-021-88130-w'},
{'key': 'e_1_3_5_7_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/febs.12936'},
{'key': 'e_1_3_5_8_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abl4784'},
{ 'key': 'e_1_3_5_9_2',
'unstructured': 'Food and Drug Administration. Fact sheet for healthcare providers: '
'emergency use authorization for Paxlovid. 2024 '
'(https://labeling.pfizer.com/ShowLabeling.aspx?id=16474).'},
{'key': 'e_1_3_5_10_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2118542'},
{ 'key': 'e_1_3_5_11_2',
'unstructured': 'Food and Drug Administration. FDA briefing document. Antimicrobial Drugs '
'Advisory Committee meeting March 16 2023 '
'(https://www.fda.gov/media/166197/download).'},
{ 'key': 'e_1_3_5_12_2',
'unstructured': 'Food and Drug Administration. Assessing COVID-19-related symptoms in '
'outpatient adult and adolescent subjects in clinical trials of drugs and '
'biological products for COVID-19 prevention or treatment. Guidance for '
'industry. February 2024 '
'(https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs).'},
{ 'key': 'e_1_3_5_13_2',
'doi-asserted-by': 'crossref',
'unstructured': 'Lewnard JA McLaughlin JM Malden D et al. Effectiveness of '
'nirmatrelvir-ritonavir against hospital admission or death: a cohort '
'study in a large US healthcare system. January 10 2023 '
'(https://www.medrxiv.org/content/10.1101/2022.10.02.22280623v2). '
'preprint.',
'DOI': '10.1101/2022.10.02.22280623'},
{ 'key': 'e_1_3_5_14_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0140-6736(22)01586-0'},
{'key': 'e_1_3_5_15_2', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M22-3565'},
{'key': 'e_1_3_5_16_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1503/cmaj.221608'},
{'key': 'e_1_3_5_17_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2204919'}],
'container-title': 'New England Journal of Medicine',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'http://www.nejm.org/doi/pdf/10.1056/NEJMoa2309003',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 4, 3]],
'date-time': '2024-04-03T21:01:17Z',
'timestamp': 1712178077000},
'score': 1,
'resource': {'primary': {'URL': 'http://www.nejm.org/doi/10.1056/NEJMoa2309003'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 4, 4]]},
'references-count': 16,
'journal-issue': {'issue': '13', 'published-print': {'date-parts': [[2024, 4, 4]]}},
'alternative-id': ['10.1056/NEJMoa2309003'],
'URL': 'http://dx.doi.org/10.1056/NEJMoa2309003',
'relation': {},
'ISSN': ['0028-4793', '1533-4406'],
'subject': ['General Medicine'],
'container-title-short': 'N Engl J Med',
'published': {'date-parts': [[2024, 4, 4]]}}
